<--GAT-->

Biomarkers Different in Acute HF Patients With, Without Diabetes

by U.S. Medicine

August 28, 2017

GRONINGEN, THE NETHERLANDS – How diabetes affects pathophysiological processes among patients with acute heart failure (AHF) is unclear, according to a new study published in the European Journal of Heart Failure.1

To add to that information, a study team led by the University of Groningen in The Netherlands and including participation from the San Francisco VAMC, analyzed a panel of 48 circulating biomarkers measured within 24 hours of admission for AHF in a subset of patients enrolled in the PROTECT trial. In patients with and without diabetes, the researchers performed a network analysis to identify correlations between measured biomarkers.

Results suggested that, compared with the 1,111 patients without diabetes, the 922 with diabetes had a higher prevalence of ischemic heart disease and traditional coronary risk factors. After multivariable adjustment, patients with and without diabetes had significantly different levels of biomarkers across a spectrum of pathophysiological domains, including inflammation (TNFR-1a, periostin), cardiomyocyte stretch (BNP), angiogenesis (VEGFR, angiogenin), and renal function (NGAL, KIM-1) (adjusted P-value <0.05).

Among patients with diabetes, network analysis revealed that periostin strongly clustered with C-reactive protein and interleukin-6. Renal markers (creatinine and NGAL) were found to be closely associated with potassium and glucose. Those findings were not seen among patients without diabetes, the researchers pointed out.

“Patients with AHF and diabetes, compared with those without diabetes, have distinct biomarker profiles,” study authors concluded. “Network analysis suggests that cardiac remodeling, inflammation, and fibrosis are closely associated with each other in patients with diabetes. Furthermore, potassium levels may be sensitive to changes in renal function as reflected by the strong renal-potassium-glucose correlation. These findings were not seen among patients without diabetes and may suggest distinct pathophysiological processes among AHF patients with diabetes.”

  1. Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Telerik JR, Davison BA, Givers MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Zeolite JA, Khan MAF, Boors AA. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. Euro J Heart Fail. 2017 Jun 21. doi: 10.1002/ejhf.912. [Epub ahead of print] PubMed PMID: 28639369.

Comments are closed here.


Related Articles

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.

VA Research Determines Which Beta Blocker Is Better in Heart Failure

ST. LOUIS—Current clinical guidelines recommend the use of beta blockers in all heart failure patients with with reduced ejection fraction (HFrEF). Which beta blocker to use—carvedilol or metoprolol succinate—remained unclear, however, according to a recent... View Article


U.S. Medicine Recommends


More From cardiology

Cardiology

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.

Cardiology

VA Research Determines Which Beta Blocker Is Better in Heart Failure

WASHINGTON—Congress announced last month that it will be opening an investigation into alleged improper influence by three civilian consultants to President Donald Trump on administration of the VA. The three men—Ike Perlmutter, CEO of Marvel... View Article

Cardiology

New VA Analysis Refutes Link Between Heart Failure, Incident Cancer

With about 350,000 patients with heart failure diagnoses being treated in the VHA, recent studies suggesting that the cardiovascular condition increases risk of cancer have been worrisome.

Cardiology

Medications, interventions underused in veterans with peripheral artery disease

Nearly 30% of veterans with peripheral artery disease (PAD) die within four years of diagnosis, while others experience limb amputation or critical limb ischemia.

Cardiology

Rank as socioeconomic proxy affects stroke outcomes in MHS patients

Do socioeconomic disparities exist in the U.S. military healthcare system with ischemic stroke admissions? A new study says they do.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up